Listing of Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

1-20. (Canceled).

21. (Currently Amended) A nasally administered pharmaceutical formulation for treating sexual dysfunction in a mammalian subject comprising a therapeutically effective amount of an apomorphine compound in ~~a~~ an aqueous formulation for enhanced nasal delivery which yields enhanced nasal absorption of said apomorphine compound to produce a therapeutic result in said subject within about 30 minutes or less without unacceptable adverse side effects in said subject.

22. (Currently Amended) The nasally administered pharmaceutical composition of Claim 21, wherein administration of said apomorphine compound in said aqueous formulation for enhanced nasal delivery yields enhanced nasal absorption of said apomorphine compound to produce a therapeutic result in said subject within about 15 minutes or less without unacceptable adverse side effects in said subject.

23. (Currently Amended) A nasally administered pharmaceutical formulation for treating sexual dysfunction in a mammalian subject comprising a therapeutically effective amount of an apomorphine compound in ~~a~~ an aqueous formulation for enhanced nasal delivery which yields enhanced nasal absorption of said apomorphine compound resulting in a time to maximal plasma concentration of said apomorphine compound in said subject of about 20 minutes or less without unacceptable adverse side effects in said subject.

24. (Currently Amended) The nasally administered pharmaceutical composition of Claim 23, wherein administration of said apomorphine compound in said aqueous formulation for enhanced nasal delivery yields enhanced nasal absorption resulting in a time to maximal plasma concentration of said apomorphine compound in said subject of about 15 minutes or less without unacceptable adverse side effects in said subject.

25. (Previously Presented) The nasally administered pharmaceutical composition of Claim 21, wherein said subject is a female.

26. (Previously Presented) The nasally administered pharmaceutical composition of Claim 23, wherein said subject is a female.

27. (Previously Presented) The nasally administered pharmaceutical composition of Claim 21, wherein said therapeutic response is selected from an improvement of sexual desire in a male or female subject, or amelioration of erectile dysfunction affecting an erectile tissue of a male or female subject.

28. (Previously Presented) The nasally administered pharmaceutical composition of Claim 23, wherein said sexual dysfunction is selected from reduced sexual desire in a male or female subject, or erectile dysfunction affecting an erectile tissue of a male or female subject.

29. (Previously Presented) The nasally administered pharmaceutical composition of Claim 21, wherein said apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

30. (Previously Presented) The nasally administered pharmaceutical composition of Claim 23, wherein said apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

31. (Currently Amended) The nasally administered pharmaceutical composition of Claim 21, wherein said ~~apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof~~ aqueous formulation for enhanced nasal delivery has a pH of between about 3.0 to 3.5.

32. (Currently Amended) The nasally administered pharmaceutical composition of Claim 23, wherein said ~~apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof~~ aqueous formulation for enhanced nasal delivery has a pH of between about 3.0 to 3.5.

33. (Withdrawn) A method of increasing sexual desire or eliciting an erectile response in a male or female mammalian subject comprising nasally administering a therapeutically effective amount of a dopamine receptor agonist in a formulation for enhanced nasal delivery which yields enhanced nasal absorption of said dopamine receptor agonist to produce a therapeutic result in said subject within about 30 minutes or less.

34. (Withdrawn) The method of Claim 33, wherein administration of said dopamine receptor agonist in said formulation for enhanced nasal delivery yields enhanced nasal absorption of said dopamine receptor agonist to produce a therapeutic result in said subject within about 15 minutes or less.

35. (Withdrawn) A method of increasing sexual desire or eliciting an erectile response in a male or female mammalian subject comprising nasally administering a therapeutically effective amount of a dopamine receptor agonist in a formulation for enhanced nasal delivery which yields enhanced nasal absorption of said dopamine receptor agonist resulting in a time to maximal plasma concentration (tmax) of said dopamine receptor agonist in said subject of about 20 minutes or less.

36. (Withdrawn) The method of claim 35, wherein administration of said dopamine receptor agonist in said formulation for enhanced nasal delivery yields enhanced nasal absorption resulting in a time to maximal plasma concentration (tmax) of said dopamine receptor agonist in said subject of about 15 minutes or less.

37. (Withdrawn) The method of Claim 33, wherein said dopamine receptor agonist is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

38. (Withdrawn) The method of Claim 35, wherein said dopamine receptor agonist is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

39. (Currently Amended) A nasally administered pharmaceutical formulation for treating difficulty in achieving or inability of achieving orgasm in a female mammalian subject comprising a therapeutically effective amount of an apomorphine compound in ~~a~~ an aqueous formulation for enhanced nasal delivery which yields enhanced nasal absorption of said apomorphine compound resulting in a time to maximal plasma concentration of said dopamine receptor agonist in said subject of about 20 minutes or less without unacceptable adverse side effects in said subject.

40. (Withdrawn) A method of reducing difficulty in achieving or inability of achieving orgasm in a female mammalian subject comprising nasally administering a therapeutically effective amount of a dopamine receptor agonist in a formulation for enhanced nasal delivery which yields enhanced nasal absorption of said dopamine receptor agonist resulting in a time to maximal plasma concentration (tmax) of said dopamine receptor agonist in said subject of about 20 minutes or less, before, during or after sexual activity.